Previous 10 | Next 10 |
Aridis Pharmaceuticals (NASDAQ:ARDS): Q3 GAAP EPS of -$1.94 misses by $1.44. Revenue of $0.51M beats by $0.21M. Cash and cash equivalents as of September 30, 2021, were approximately $18.2M. Press Release For further details see: Aridis Pharmaceuticals EPS misses by $1.44, beats o...
Aridis Pharmaceuticals Announces Third Quarter 2021 Results Executed AstraZeneca in-licensing deal of Phase 3-ready antibody, suvratoxumab, in July 2021 Bolstered financial position with approx. $25 million in equity financing in August 2021 PR Newswire LOS GAT...
Aridis Pharmaceuticals Announces Second Quarter 2021 Results -- In-licensed Phase 3-ready antibody, suvratoxumab, from AstraZeneca -- Raised approximately $25 million in equity financing -- Confirmed that SARS-CoV-2 antibody combination AR-712 is active against the Delta...
Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to Market PR Newswire LOS GATOS, Calif. , Aug. 2, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discove...
Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) traded at a new 52-week low today of $4.59. So far today approximately 832,000 shares have been exchanged, as compared to an average 30-day volume of 258,000 shares. Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is enga...
Aridis Pharmaceuticals' COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC) CoVIC's animal efficacy data shows that Aridis' AR-711 mAb is among the top 5 most potent out of more than 350 COVID mAbs that hav...
Gainers: Freeline Therapeutics (FRLN) +88%, Cytokinetics CYTK +49%, NRx Pharmaceuticals NRXP +37%, Allied Healthcare Products (AHPI) +19%, Aethlon Medical (AEMD) +16%.Losers: China SXT Pharmaceuticals (SXTC) -21%, Atossa Therapeutics (ATOS)...
Aridis Pharmaceuticals (ARDS) announces that it has entered into an exclusive worldwide licensing agreement with AstraZeneca (AZN) to in-license suvratoxumab, in a deal worth as much as $126M. Suvratoxumab is a late-stage monoclonal antibody ((mAb)) candidate being developed for preventi...
Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca PR Newswire LOS GATOS, Calif. , July 19, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered...
CIPhotos/iStock via Getty Images Shares of Aridis Pharmaceuticals ([[ARDS]] -18.5%) are down sharply in afternoon trading, a day after shares surged following the release of encouraging preclinical data for its COVID-19 antibody cocktail. In an animal model, AR-712 was effective in neutralizi...
News, Short Squeeze, Breakout and More Instantly...
Aridis Pharmaceuticals Inc. Company Name:
ARDS Stock Symbol:
NASDAQ Market:
Aridis Pharmaceuticals Inc. Website:
Biomerieux (BMXMF) is expected to report for Q1 2024 Conn's Inc. (CONN) is expected to report $-0.65 for Q1 2025 Cognetivity Neurosciences Ltd (CGNSF) is expected to report for quarter end 2024-04-30 Aridis Pharmaceuticals Inc. (ARDS) is expected to report for Q1 2024 China Jo-Jo ...
DS Smith Plc. (DITHF) is expected to report for Q4 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Harbour Energy Plc ADR (HBRIY) is expected to report for Q1 2024 Bayerische Motoren Werke AG (BAMXF) is expected to report for Q1 2024 ...
Commercial Metals Company (CMC) is expected to report $1 for Q3 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 GMS Inc. (GMS) is expected to report $2.04 for Q4 2024 China Jo-Jo Drugstores Inc. (CJJD) is expected to report for Q4 2024 Eiger BioPharmaceuticals Inc. (EIGR...